ArticleScientific reports2026

Tumor genome and microenvironment alteration by trastuzumab deruxtecan as neoadjuvant therapy for HER2-mutant NSCLC.

Jiangyang Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.